Psoriasis comorbidities and clinical implications when using biologics
Background Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects...
Gespeichert in:
| Veröffentlicht in: | Dermatological reviews 2021-10, Vol.2 (5), p.236-244 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 5 |
| container_start_page | 236 |
| container_title | Dermatological reviews |
| container_volume | 2 |
| creator | Kang, Julianna S. Balogh, Esther A. Feldman, Steven R. |
| description | Background
Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects on a comorbidity can guide treatment decisions and direct further workup to screen for markers of these comorbidities.
Methods
A literature search was performed to develop treatment recommendations for psoriasis patients in the background of common comorbidities when considering biologic agents.
Results
Psoriatic arthritis, inflammatory bowel disease, metabolic syndrome, nonalcoholic fatty liver disease, depression, and malignancies are comorbidities associated with psoriasis that can be affected by certain biologic agents.
Conclusion
Considerations to make when treating a patient with psoriasis include the severity of disease, the presence of comorbidities, and symptomology that can interact with biologic agents. |
| doi_str_mv | 10.1002/der2.89 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_der2_89</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DER289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1399-feb0733fea16e832b572254569da3082e29aed7e0ad32b15e539afd84c65f3593</originalsourceid><addsrcrecordid>eNp10E1LAzEQBuAgCpZa_Au5eZCt-dhskqPUVoWCInpesslsHdndlKRS-u_dUg9ePM0L8zAMLyHXnM05Y-IuQBJzY8_IRFRSF7o09vxPviSznL_YKLnmzIgJWb3mmNBlzNTHPqYGA-4QMnVDoL7DAb3rKPbbbgw7jEOm-08Y6HfGYUMbjF3coM9X5KJ1XYbZ75ySj9XyffFUrF8enxf368JzaW3RQsO0lC04XoGRolFaCFWqygYnx39AWAdBA3NhXHIFSlrXBlP6SrVSWTklN6e7PsWcE7T1NmHv0qHmrD42UB8bqM1R3p7kHjs4_Mfqh-WbGPUPfjpc1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psoriasis comorbidities and clinical implications when using biologics</title><source>Wiley Journals</source><creator>Kang, Julianna S. ; Balogh, Esther A. ; Feldman, Steven R.</creator><creatorcontrib>Kang, Julianna S. ; Balogh, Esther A. ; Feldman, Steven R.</creatorcontrib><description>Background
Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects on a comorbidity can guide treatment decisions and direct further workup to screen for markers of these comorbidities.
Methods
A literature search was performed to develop treatment recommendations for psoriasis patients in the background of common comorbidities when considering biologic agents.
Results
Psoriatic arthritis, inflammatory bowel disease, metabolic syndrome, nonalcoholic fatty liver disease, depression, and malignancies are comorbidities associated with psoriasis that can be affected by certain biologic agents.
Conclusion
Considerations to make when treating a patient with psoriasis include the severity of disease, the presence of comorbidities, and symptomology that can interact with biologic agents.</description><identifier>ISSN: 2637-7489</identifier><identifier>EISSN: 2637-7489</identifier><identifier>DOI: 10.1002/der2.89</identifier><language>eng</language><subject>adverse effect ; biologics ; comorbidities ; prevalence ; psoriasis</subject><ispartof>Dermatological reviews, 2021-10, Vol.2 (5), p.236-244</ispartof><rights>2021 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1399-feb0733fea16e832b572254569da3082e29aed7e0ad32b15e539afd84c65f3593</citedby><cites>FETCH-LOGICAL-c1399-feb0733fea16e832b572254569da3082e29aed7e0ad32b15e539afd84c65f3593</cites><orcidid>0000-0003-0340-3027 ; 0000-0001-5577-8838 ; 0000-0002-0090-6289</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fder2.89$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fder2.89$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Kang, Julianna S.</creatorcontrib><creatorcontrib>Balogh, Esther A.</creatorcontrib><creatorcontrib>Feldman, Steven R.</creatorcontrib><title>Psoriasis comorbidities and clinical implications when using biologics</title><title>Dermatological reviews</title><description>Background
Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects on a comorbidity can guide treatment decisions and direct further workup to screen for markers of these comorbidities.
Methods
A literature search was performed to develop treatment recommendations for psoriasis patients in the background of common comorbidities when considering biologic agents.
Results
Psoriatic arthritis, inflammatory bowel disease, metabolic syndrome, nonalcoholic fatty liver disease, depression, and malignancies are comorbidities associated with psoriasis that can be affected by certain biologic agents.
Conclusion
Considerations to make when treating a patient with psoriasis include the severity of disease, the presence of comorbidities, and symptomology that can interact with biologic agents.</description><subject>adverse effect</subject><subject>biologics</subject><subject>comorbidities</subject><subject>prevalence</subject><subject>psoriasis</subject><issn>2637-7489</issn><issn>2637-7489</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10E1LAzEQBuAgCpZa_Au5eZCt-dhskqPUVoWCInpesslsHdndlKRS-u_dUg9ePM0L8zAMLyHXnM05Y-IuQBJzY8_IRFRSF7o09vxPviSznL_YKLnmzIgJWb3mmNBlzNTHPqYGA-4QMnVDoL7DAb3rKPbbbgw7jEOm-08Y6HfGYUMbjF3coM9X5KJ1XYbZ75ySj9XyffFUrF8enxf368JzaW3RQsO0lC04XoGRolFaCFWqygYnx39AWAdBA3NhXHIFSlrXBlP6SrVSWTklN6e7PsWcE7T1NmHv0qHmrD42UB8bqM1R3p7kHjs4_Mfqh-WbGPUPfjpc1g</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Kang, Julianna S.</creator><creator>Balogh, Esther A.</creator><creator>Feldman, Steven R.</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-0340-3027</orcidid><orcidid>https://orcid.org/0000-0001-5577-8838</orcidid><orcidid>https://orcid.org/0000-0002-0090-6289</orcidid></search><sort><creationdate>202110</creationdate><title>Psoriasis comorbidities and clinical implications when using biologics</title><author>Kang, Julianna S. ; Balogh, Esther A. ; Feldman, Steven R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1399-feb0733fea16e832b572254569da3082e29aed7e0ad32b15e539afd84c65f3593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse effect</topic><topic>biologics</topic><topic>comorbidities</topic><topic>prevalence</topic><topic>psoriasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Julianna S.</creatorcontrib><creatorcontrib>Balogh, Esther A.</creatorcontrib><creatorcontrib>Feldman, Steven R.</creatorcontrib><collection>CrossRef</collection><jtitle>Dermatological reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Julianna S.</au><au>Balogh, Esther A.</au><au>Feldman, Steven R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriasis comorbidities and clinical implications when using biologics</atitle><jtitle>Dermatological reviews</jtitle><date>2021-10</date><risdate>2021</risdate><volume>2</volume><issue>5</issue><spage>236</spage><epage>244</epage><pages>236-244</pages><issn>2637-7489</issn><eissn>2637-7489</eissn><abstract>Background
Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects on a comorbidity can guide treatment decisions and direct further workup to screen for markers of these comorbidities.
Methods
A literature search was performed to develop treatment recommendations for psoriasis patients in the background of common comorbidities when considering biologic agents.
Results
Psoriatic arthritis, inflammatory bowel disease, metabolic syndrome, nonalcoholic fatty liver disease, depression, and malignancies are comorbidities associated with psoriasis that can be affected by certain biologic agents.
Conclusion
Considerations to make when treating a patient with psoriasis include the severity of disease, the presence of comorbidities, and symptomology that can interact with biologic agents.</abstract><doi>10.1002/der2.89</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0340-3027</orcidid><orcidid>https://orcid.org/0000-0001-5577-8838</orcidid><orcidid>https://orcid.org/0000-0002-0090-6289</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2637-7489 |
| ispartof | Dermatological reviews, 2021-10, Vol.2 (5), p.236-244 |
| issn | 2637-7489 2637-7489 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_der2_89 |
| source | Wiley Journals |
| subjects | adverse effect biologics comorbidities prevalence psoriasis |
| title | Psoriasis comorbidities and clinical implications when using biologics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriasis%20comorbidities%20and%20clinical%20implications%20when%20using%20biologics&rft.jtitle=Dermatological%20reviews&rft.au=Kang,%20Julianna%20S.&rft.date=2021-10&rft.volume=2&rft.issue=5&rft.spage=236&rft.epage=244&rft.pages=236-244&rft.issn=2637-7489&rft.eissn=2637-7489&rft_id=info:doi/10.1002/der2.89&rft_dat=%3Cwiley_cross%3EDER289%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |